Skip to main content
Top
Published in: International Urology and Nephrology 5/2024

15-12-2023 | Prostate Cancer | Urology - Original Paper

TRAIP suppressed apoptosis and cell cycle to promote prostate cancer proliferation via TRAF2–PI3K–AKT pathway activation

Authors: Yuan Gu, Chaozhao Liang

Published in: International Urology and Nephrology | Issue 5/2024

Login to get access

Abstract

Background

TRAF-interacting protein (TRAIP) is a RING-type E3 ubiquitin ligase, which has been implicated in various cellular processes and participated in various cancers as an oncogene. However, the function and potential mechanism of TRAIP in prostate cancer (PCa) have not been investigated so far.

Methods

Public TGCA data were used to evaluate the expression profile of TRAIP in prostatic tumors. The relative expression of TRAIP and TRAF2 in PCa tissues and tumor cell lines was detected by qPCR, western blot, and IHC staining. Next, TRAIP knockdown and overexpression plasmids were constructed and transfected into PCa cell lines. Moreover, cell proliferation, invasion, migration, and apoptosis were measured by colony formation, Transwell, wound healing, and flow cytometry assays. Subsequently, cell cycle and signaling pathway-related proteins were tested by western blot. Finally, the effect of TRAIP on PCa was measured based on the nude mouse xenograft model.

Results

TRAIP was significantly upregulated in PCa tissues and tumor cell lines. In addition, TRAIP promoted cell proliferation, invasion, and migration of PCa cell lines. Such an oncogenic property was mediated by the cell cycle arrest and the inhibition of apoptosis, as indicated by different functional assays and the expression of cell cycle and apoptosis regulatory proteins in cultured cells. Moreover, TRAIP combined with TRAF2 to activate PI3K/AKT pathway. Finally, TRAIP depletion suppressed the growth of tumors and cell proliferation in vivo.

Conclusions

Our study first revealed that TRAIP promoted tumor progression and identified it as a potential therapeutic target for PCa patients in the future.
Appendix
Available only for authorised users
Literature
15.
17.
go back to reference De Blasio C, Verma N, Moretti M, Cialfi S, Zonfrilli A, Franchitto M, Truglio F, De Smaele E, Ichijo H, Naguro I, Screpanti I, Talora C (2021) Functional cooperation between ASK1 and p21(Waf1/Cip1) in the balance of cell-cycle arrest, cell death and tumorigenesis of stressed keratinocytes. Cell Death Discovery 7 (1). https://doi.org/10.1038/s41420-021-00459-3 De Blasio C, Verma N, Moretti M, Cialfi S, Zonfrilli A, Franchitto M, Truglio F, De Smaele E, Ichijo H, Naguro I, Screpanti I, Talora C (2021) Functional cooperation between ASK1 and p21(Waf1/Cip1) in the balance of cell-cycle arrest, cell death and tumorigenesis of stressed keratinocytes. Cell Death Discovery 7 (1). https://​doi.​org/​10.​1038/​s41420-021-00459-3
Metadata
Title
TRAIP suppressed apoptosis and cell cycle to promote prostate cancer proliferation via TRAF2–PI3K–AKT pathway activation
Authors
Yuan Gu
Chaozhao Liang
Publication date
15-12-2023
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 5/2024
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-023-03890-w

Other articles of this Issue 5/2024

International Urology and Nephrology 5/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine